Sign In
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
By signing in or creating an account, you agree with Associated Broadcasting Company's Terms & Conditions and Privacy Policy.
New Delhi: Dr. Reddy's Laboratories came up with its quarterly results for the April-June quarter of FY26 on Wednesday, 23rd July 2025. The company reported a 1 percent increase in consolidated net profit to Rs 1410 crore during Q1 FY26. The Hyderabad-based major drug company had amassed a profit of Rs 1392 crore in the same quarter of the previous fiscal year, FY25.
The operational revenue of the company has increased to Rs 8545 crore in the said period, up from Rs 7673 crore in the corresponding period of the previous fiscal year, FY25.
"We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio," said Dr. Reddy's Co-Chairman and MD G. V. Prasad.
The pricing pressure on Lenalidomide is expected to intensify in the US generics market, he noted.
"We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity, and business development," Prasad said.
The shares of the Dr. Reddy's lab closed at Rs 1247.55 apiece on Wednesday, 23rd July 2025, as per the data obtained from the Bombay Stock Exchange, and the shares went up by 0.58 percent in the trading session. The shares have given a negative return of 2.95 percent in the last one month, whereas the stock has given a negative return of around 7 percent in the last one year.
The price-to-earnings (P/E) ratio of the company stands at 19.46. The 52-week high of the stock is Rs 1,420.20 per equity share, whereas the 52-week low of the stock is Rs 1,025.90 per equity share. The market capitalisation of the company stands at Rs 103522 crore.
The company is an India-based global pharmaceutical company. The pharma firm offers diverse products, including Active Pharmaceutical Ingredients (APIs), generic medicine, and OTC (over-the-counter) drugs. The company's major areas of focus are in gastrointestinal, cardiovascular, diabetology, oncology, painkiller, and dermatological domains.
(Disclaimer: This article is only meant to provide information. TV9 does not recommend buying or selling shares or subscriptions of any IPO, Mutual Funds, precious metals, commodity, REITs, INVITs, any form of alternative investment instruments and crypto assets.))
